Trinity Biotech (TRIB) Short term Debt (2021 - 2025)

Trinity Biotech (TRIB) has reported Short term Debt for 5 consecutive years, with $210000.0 the latest figure, recorded in Q2 2025.

• Quarterly Short term Debt changed 0.0% year-over-year to $210000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $210000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $210000.0, changed 0.0% from the prior year.
• Short term Debt steadied at $210000.0 in Q2 2025 per TRIB's latest filing, from $210000.0 in the prior quarter.
• Over the last five years, Short term Debt for TRIB reached as high as $83.3 million in Q4 2021 and fell as low as $210000.0 in Q2 2022.
• A 5-year average of $14.1 million and a median of $210000.0 in 2022 frame the typical range for Short term Debt.
• The largest YoY upside for Short term Debt was 0.0% in 2024 against a maximum downside of 0.0% in 2024.
• Year by year, Short term Debt stood at $83.3 million in 2021, then slumped by 99.75% to $210000.0 in 2022, then changed by 0.0% to $210000.0 in 2023, then changed by 0.0% to $210000.0 in 2024, then changed by 0.0% to $210000.0 in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $210000.0, $210000.0, and $210000.0 for Q2 2025, Q4 2024, and Q2 2024 respectively.